Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration

Milena M. McLaughlin, Abeer T. Ammar, Lana Gerzenshtein, Kimberly K. Scarsi

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Conclusion: Clinicians should utilize these recommendations in the context of each individual patient, taking into consideration patient-specific factors and severity of illness. Future pharmacokinetic research correlating plasma and intracellular concentrations of NRTIs during CVVH is warranted to elucidate appropriate dosing.

Background and Objective: Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of this study was to formulate NRTI dosing recommendations for adults receiving CVVH.

Methods: A mathematical formula that estimates the amount of drug likely to be removed during CVVH at various flow rates was used to calculate the supplemental NRTI dose required during CVVH.

Results: A proposed table of dosing recommendations for NRTIs during CVVH is presented.

Original languageEnglish (US)
Pages (from-to)275-280
Number of pages6
JournalClinical Drug Investigation
Issue number4
StatePublished - Mar 21 2015

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration'. Together they form a unique fingerprint.

Cite this